Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study record history was updated with new entries on 2026-03-27 and 2026-03-30. Earlier updates from 2026-03-06 and 2026-03-09 were removed.SummaryDifference0.1%

- Check17 days agoChange DetectedRevision tag updated to v3.5.0 and the previous tag v3.4.3 was removed.SummaryDifference0.0%

- Check25 days agoChange DetectedThe study locations list was updated to reflect 56 sites, with additions across multiple countries and removals of several previously listed sites.SummaryDifference3%

- Check32 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 with no visible changes to core study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision metadata updated from v3.4.0 to v3.4.1; no study details or user-facing functionality were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.